Please assess the completion status of the following clinical trial:

Trial Title: Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The presence of SCC of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx, or larynx must be confirmed by histological examination of a tissue sample (e.g., biopsy) obtained within 1 month of the patient receiving the study treatment.~2. Recurrent or second primary disease in patients where surgical resection is seen as an option for disease control.~3. The length of the longest diameter of the study lesion must be \< 5 cm and the calculated treatment volume must be \< 60.0 cm3 (tumor volume plus a 0.5 cm margin around the tumor) for the study lesion \[where treatment volume = 0.5 (A+1) (B+1)2 and where A = length of the longest diameter (cm), B = the next longest diameter perpendicular to A (cm)\].~4. Tumor burden must be completely encompassed by surgery or bleomycin-EPT.~5. Age: 18 years or older.~6. Men and women of childbearing potential must use physician approved contraceptive methods for 7 days following bleomycin-EPT.~7. Hematopoietic status:~   * Absolute neutrophil count (ANC) \> 1000/uL~  * Platelets \> 75,000/mm3~  * Prothrombin time: international normalized ratio (PT: INR) 1.5 (correctable with vitamin K injection)~8. Blood chemistry status:~   * Transaminases \< 3 times upper limit of normal~  * Total bilirubin \< 2.5 mg/dL~  * Creatinine \< 2.5mg/dL~9. A written Informed Consent form must be signed prior to the patient receiving any study procedures or treatments.~Exclusion Criteria:~1. Patients with tumors suspected of involving a 50% or greater encasement of a blood vessel as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan.~2. Patients with tumors having bone invasion.~3. Patients with any metallic implants in the treatment field.~4. Patients with hypersensitivity to bleomycin.~5. Patients who have received or will exceed a total lifetime dose of bleomycin greater than 400 units.~6. Patients deemed unsuitable for general anesthesia.~7. Patients with a significant history of emphysema or pulmonary fibrosis.~8. Patients with indwelling cardiac pacemakers who cannot tolerate a period with pacemaker turned off.~9. Patients with a history of uncontrolled cardiac arrhythmia.~10. Women who are pregnant, or are nursing. Women of childbearing potential must have a negative beta human chorionic gonadotropin (beta hCG) test within 7 days of study treatment.~11. Radiation therapy to the treatment area within 8 weeks of study treatment.~12. Chemotherapy or other cancer therapy (e.g., surgery, cryotherapy, etc.) to the treatment area within 4 weeks of study treatment.~13. Patients participating in a clinical study for an investigational drug or device within 4 weeks prior to the study treatment.~14. Patients previously randomized to this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery Control (Type: ACTIVE_COMPARATOR): Patients receive surgical excision of their tumor.
- MedPulser EPT (Type: EXPERIMENTAL): Patients receive electroporation with injection of Bleomycin Sulfate.

Based on this trial design, predict the completion outcome and termination type (if applicable).